LU92233I2 - Sativex et ses dérivés pharmaceutiquement acceptables - Google Patents
Sativex et ses dérivés pharmaceutiquement acceptablesInfo
- Publication number
- LU92233I2 LU92233I2 LU92233C LU92233C LU92233I2 LU 92233 I2 LU92233 I2 LU 92233I2 LU 92233 C LU92233 C LU 92233C LU 92233 C LU92233 C LU 92233C LU 92233 I2 LU92233 I2 LU 92233I2
- Authority
- LU
- Luxembourg
- Prior art keywords
- formulation
- solvent
- sativex
- cannabinoids
- pharmaceutically acceptable
- Prior art date
Links
- SSNHGLKFJISNTR-DYSNNVSPSA-N (6ar,10ar)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol;2-[(1r,6r)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1.C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 SSNHGLKFJISNTR-DYSNNVSPSA-N 0.000 title 1
- 238000009472 formulation Methods 0.000 abstract 5
- 239000000203 mixture Substances 0.000 abstract 5
- 229930003827 cannabinoid Natural products 0.000 abstract 4
- 239000003557 cannabinoid Substances 0.000 abstract 4
- 229940065144 cannabinoids Drugs 0.000 abstract 3
- 239000006184 cosolvent Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 239000002904 solvent Substances 0.000 abstract 2
- 239000003995 emulsifying agent Substances 0.000 abstract 1
- 239000003380 propellant Substances 0.000 abstract 1
- 239000007921 spray Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Dispersion Chemistry (AREA)
- Immunology (AREA)
- Nutrition Science (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Physiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/218,989 US6946150B2 (en) | 2002-08-14 | 2002-08-14 | Pharmaceutical formulation |
| GB0218930A GB2392093B (en) | 2002-08-14 | 2002-08-14 | Pharmaceutical formulations |
| PCT/GB2003/003574 WO2004016246A1 (fr) | 2002-08-14 | 2003-08-14 | Preparations liquides cannabinoides destinees a etre administrees par muqueuses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LU92233I2 true LU92233I2 (fr) | 2013-08-26 |
Family
ID=31889678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU92233C LU92233I2 (fr) | 2002-08-14 | 2013-06-26 | Sativex et ses dérivés pharmaceutiquement acceptables |
Country Status (16)
| Country | Link |
|---|---|
| EP (2) | EP1542657B8 (fr) |
| JP (1) | JP4515908B2 (fr) |
| KR (1) | KR101008609B1 (fr) |
| AT (1) | ATE533472T1 (fr) |
| AU (2) | AU2003253005B2 (fr) |
| CA (1) | CA2454644C (fr) |
| CY (1) | CY1112523T1 (fr) |
| DK (2) | DK1542657T3 (fr) |
| ES (2) | ES2377819T3 (fr) |
| FR (1) | FR14C0025I2 (fr) |
| LU (1) | LU92233I2 (fr) |
| MX (1) | MXPA05001567A (fr) |
| PL (1) | PL215220B1 (fr) |
| PT (2) | PT1542657E (fr) |
| SI (1) | SI1542657T1 (fr) |
| WO (1) | WO2004016246A1 (fr) |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2280343T3 (es) | 2000-03-09 | 2007-09-16 | Gw Pharma Limited | Composiciones farmaceuticas que contienen cannabis. |
| GB2414933B (en) * | 2004-06-08 | 2009-07-15 | Gw Pharma Ltd | Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis |
| AU2005305675B2 (en) * | 2004-11-16 | 2012-12-13 | Jazz Pharmaceuticals Operations Uk Limited | New use for cannabinoid |
| GB0425248D0 (en) | 2004-11-16 | 2004-12-15 | Gw Pharma Ltd | New use for cannabinoid |
| GB2434312B (en) * | 2006-01-18 | 2011-06-29 | Gw Pharma Ltd | Cannabinoid-containing plant extracts as neuroprotective agents |
| GB2439393B (en) * | 2006-06-23 | 2011-05-11 | Gw Pharma Ltd | Cannabinoids for use in the treatment of neuropathic pain |
| US8039509B2 (en) | 2006-11-10 | 2011-10-18 | Johnson Matthey Public Limited Company | Composition comprising (−)-Δ9-trans-tetrahydrocannabinol |
| US8980940B2 (en) | 2006-11-10 | 2015-03-17 | Johnson Matthey Public Limited Company | Stable cannabinoid compositions and methods for making and storing them |
| US9035130B2 (en) | 2007-05-31 | 2015-05-19 | Gw Pharma Limited | Reference plant, a method for its production, extracts obtained therefrom and their use |
| GB2449691A (en) | 2007-05-31 | 2008-12-03 | Gw Pharma Ltd | A reference plant lacking medicinal active compound expression |
| GB2450753B (en) * | 2007-07-06 | 2012-07-18 | Gw Pharma Ltd | New Pharmaceutical formulation |
| GB2471523A (en) | 2009-07-03 | 2011-01-05 | Gw Pharma Ltd | Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy |
| TWI583374B (zh) * | 2010-03-30 | 2017-05-21 | Ｇｗ伐瑪有限公司 | 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途 |
| GB2487712B (en) | 2011-01-04 | 2015-10-28 | Otsuka Pharma Co Ltd | Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy |
| GB2524689B (en) | 2011-05-20 | 2016-01-27 | Gw Pharma Ltd | Cannabinoids for use in the treatment of neuropathic pain |
| GB201111261D0 (en) | 2011-07-01 | 2011-08-17 | Gw Pharma Ltd | Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders |
| GB2495118B (en) | 2011-09-29 | 2016-05-18 | Otsuka Pharma Co Ltd | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| GB2496688B (en) * | 2011-11-21 | 2016-06-29 | Gw Pharma Ltd | Tetrahydrocannabivarin for use in the treatment of intestinal inflammatory diseases |
| US8741341B2 (en) * | 2012-05-07 | 2014-06-03 | Insys Therapeutics, Inc. | Manufacturing and packaging room temperature stable dronabinol capsules |
| GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
| GB2527599A (en) | 2014-06-27 | 2015-12-30 | Gw Pharma Ltd | Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy |
| BR112017014375A2 (pt) * | 2014-07-18 | 2019-12-31 | Medipath, Inc. | composições e métodos para administração fisiológica usando canabidiol. |
| GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2531281A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| GB2531278A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| CA3135893C (fr) | 2014-10-21 | 2023-11-14 | United Cannabis Corp. | Extraits de cannabis et procedes de preparation et d'utilisation |
| ES2761776T3 (es) | 2014-12-22 | 2020-05-21 | Suda Pharmaceuticals Ltd | Prevención y tratamiento de la enfermedad metastásica en pacientes con cáncer trombocitótico |
| GB2539472A (en) | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2541191A (en) | 2015-08-10 | 2017-02-15 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2548873B (en) | 2016-03-31 | 2020-12-02 | Gw Res Ltd | Use of Cannabidiol in the Treatment of SturgeWeber Syndrome |
| GB2549278B (en) | 2016-04-11 | 2021-02-17 | Gw Res Ltd | Use of cannabidivarin in the treatment of autism spectrum disorder |
| AU2017290107A1 (en) | 2016-06-29 | 2019-01-17 | CannScience Innovations Inc. | Decarboxylated cannabis resins, uses thereof and methods of making same |
| GB2551987A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Oral cannabinoid formulations |
| GB2551986A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Parenteral formulations |
| GB2553139A (en) | 2016-08-25 | 2018-02-28 | Gw Res Ltd | Use of cannabinoids in the treatment of multiple myeloma |
| US10188628B1 (en) | 2016-10-27 | 2019-01-29 | Alvin Kershman | Release composition for derivatives of Cannabaceae |
| GB2557921A (en) | 2016-12-16 | 2018-07-04 | Gw Res Ltd | Use of cannabinoids in the treatment of angelman syndrome |
| GB2559774B (en) | 2017-02-17 | 2021-09-29 | Gw Res Ltd | Oral cannabinoid formulations |
| GB2560019A (en) | 2017-02-27 | 2018-08-29 | Gw Res Ltd | Use of cannabinoids in the treatment of leukaemia |
| AU2018239671B2 (en) | 2017-03-24 | 2024-08-15 | Trait Biosciences, Inc. | High level In vivo biosynthesis and isolation of water-soluble cannabinoids in plant systems |
| GB2564383B (en) | 2017-06-23 | 2021-04-21 | Gw Res Ltd | Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex |
| US11946059B2 (en) | 2017-07-11 | 2024-04-02 | Trait Biosciences, Inc. | In vivo generation of water-soluble cannabinoids in plant cell suspension cultures |
| US11905543B2 (en) | 2017-07-11 | 2024-02-20 | Trait Biosceinces, Inc. | In vivo generation of water-soluble acetylated cannabinoid glycoside compounds in plant cell suspension cultures |
| EP3730145A1 (fr) | 2017-07-11 | 2020-10-28 | Trait Biosciences, Inc. | Génération de composés cannabinoïdes solubles dans l'eau dans une levure et des cultures en suspension de cellules végétales et compositions de matière |
| SG11202002169TA (en) * | 2017-09-15 | 2020-04-29 | Zelda Therapeutics Operations Pty Ltd | Composition and method for treating autism |
| WO2019104442A1 (fr) * | 2017-11-30 | 2019-06-06 | Canopy Growth Corporation | Formes pharmaceutiques liquides, procédés de préparation et utilisation |
| GB2568929A (en) | 2017-12-01 | 2019-06-05 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2569961B (en) | 2018-01-03 | 2021-12-22 | Gw Res Ltd | Pharmaceutical |
| WO2019191830A1 (fr) * | 2018-04-04 | 2019-10-10 | Vincenzo Maida | Formulations topiques de cannabinoïdes et produits d'instillation, kits et méthodes de traitement de plaies tégumentaires, et utilisations associées |
| GB201806953D0 (en) | 2018-04-27 | 2018-06-13 | Gw Res Ltd | Cannabidiol Preparations |
| EP3790543A4 (fr) | 2018-05-11 | 2022-03-30 | Rhodes Technologies Inc. | Compositions et formes posologiques pour administration orale |
| WO2019227167A1 (fr) * | 2018-06-01 | 2019-12-05 | The University Of Sydney | Compositions et traitements |
| CA3103504A1 (fr) | 2018-06-15 | 2019-12-19 | CannPal Animal Therapeutics Limited | Composition de cannabinoides et methodes de traitement utilisant cette derniere |
| US11504416B2 (en) | 2018-09-04 | 2022-11-22 | Paw Power, Inc. | Formulation with cannabinoids |
| AU2019441432B2 (en) * | 2019-04-17 | 2025-10-16 | Silver Stallion GmbH | Extraction of cannabinoids, flavonoids and terpenes from cannabis |
| US10925853B2 (en) | 2019-04-17 | 2021-02-23 | Nordiccan A/S | Oral cannabinoid tablet |
| US12178797B2 (en) | 2019-05-03 | 2024-12-31 | Zyus Life Sciences Inc. | Formulation for pain management |
| US12220396B2 (en) | 2019-05-03 | 2025-02-11 | Zyus Life Sciences Inc. | Formulation for pain management |
| KR102445087B1 (ko) * | 2019-05-03 | 2022-09-20 | 자이우스 라이프 사이언시스 아이엔씨. | 통증 관리용 제형 |
| US20220264947A1 (en) * | 2019-07-22 | 2022-08-25 | Angus RITTENBURG | Cartridge for dispensing products and methods for their manufacture |
| WO2021046189A1 (fr) | 2019-09-06 | 2021-03-11 | Quicksilver Scientific, Inc. | Systèmes de distribution de microémulsion pour boissons à base d'eau |
| WO2021055937A1 (fr) * | 2019-09-20 | 2021-03-25 | Good Design, Inc. | Cartouche pour distribuer des produits et procédés pour leur fabrication |
| EP4037663A1 (fr) | 2019-10-03 | 2022-08-10 | Starton Therapeutics, Inc. | Administration transdermique de dronabinol |
| US12409131B2 (en) | 2019-10-03 | 2025-09-09 | Pike Therapeutics Usa, Inc. | Transdermal delivery of dronabinol |
| US12016829B2 (en) | 2019-10-11 | 2024-06-25 | Pike Therapeutics Inc. | Pharmaceutical composition and method for treating seizure disorders |
| US12186280B2 (en) | 2019-10-11 | 2025-01-07 | Pike Therapeutics Inc. | Pharmaceutical composition and method for treating seizure disorders |
| CN114555068A (zh) | 2019-10-14 | 2022-05-27 | 长矛治疗股份有限公司1219014 B.C.有限公司 | 大麻二酚的透皮给药 |
| US12268699B2 (en) | 2019-10-14 | 2025-04-08 | Pike Therapeutics Inc. | Transdermal delivery of tetrahydrocannabinol |
| US12121617B2 (en) | 2019-10-14 | 2024-10-22 | Pike Therapeutics Inc. | Transdermal delivery of cannabidiol |
| GB202002754D0 (en) | 2020-02-27 | 2020-04-15 | Gw Res Ltd | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
| WO2022011393A1 (fr) | 2020-07-08 | 2022-01-13 | Shaman Naturals, Llc | Compositions pour la prévention et le traitement du diabète |
| AU2021318553A1 (en) | 2020-07-28 | 2023-03-23 | Impello Biosciences Inc. | Methods and compositions for altering secondary metabolites in plants |
| CA3173494A1 (fr) * | 2020-09-24 | 2022-03-31 | Michael Foster DAVIS | Formulation |
| US11160757B1 (en) | 2020-10-12 | 2021-11-02 | GW Research Limited | pH dependent release coated microparticle cannabinoid formulations |
| CA3199891A1 (fr) | 2020-11-24 | 2022-06-02 | Ruth Gallily | Derives cannabinoides et leur utilisation dans le traitement de l'inflammation et/ou de la douleur et/ou de l'obesite |
| KR102489407B1 (ko) * | 2021-01-18 | 2023-01-17 | 주식회사 네이처센스 | 대마 추출물을 유효성분으로 포함하는 통증 완화 및 스트레스 관련 질환 예방 및 개선용 조성물 |
| WO2022162711A1 (fr) * | 2021-01-28 | 2022-08-04 | Specchiasol S.R.L. | Composition pour le traitement d'états douloureux et/ou inflammatoires |
| US12029720B2 (en) | 2021-04-29 | 2024-07-09 | Tilray Brands, Inc. | Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof |
| WO2023043826A1 (fr) | 2021-09-14 | 2023-03-23 | Transport Authority, Inc. | Systèmes et méthodes d'administration précise et réitérable d'ingrédients pharmaceutiques actifs |
| EP4568702A1 (fr) | 2022-08-12 | 2025-06-18 | Jazz Pharmaceuticals Research UK Limited | Formes posologiques solides orales comprenant des cannabinoïdes |
| EP4483872A1 (fr) * | 2023-06-30 | 2025-01-01 | Mabewo Phytopharm AG | Composition cannabinoïde pour utilisation dans le traitement de la douleur et/ou de l'inflammation |
| WO2025003517A1 (fr) * | 2023-06-30 | 2025-01-02 | Mabewo Phytopharm Ag | Composition de cannabinoïdes destinée à être utilisée dans le traitement de la douleur et/ou de l'inflammation |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3560625A (en) | 1967-02-20 | 1971-02-02 | Colgate Palmolive Co | Method of,and formulations for,introducing alkoxybenzamides into the systemic circulatory system |
| DE3522550A1 (de) | 1985-06-24 | 1987-01-02 | Klinge Co Chem Pharm Fab | Aufspruehbare pharmazeutische zubereitung fuer die topische anwendung |
| US5165093A (en) * | 1992-03-23 | 1992-11-17 | The Titan Corporation | Interstitial X-ray needle |
| GB9807639D0 (en) * | 1998-04-14 | 1998-06-10 | Kennedy Rheumatology Inst | Anti-inflammatory agents |
| CA2341035A1 (fr) * | 1999-07-08 | 2001-01-18 | Orlando Hung | Administration pulmonaire de cannabinoides encapsules dans des liposomes |
| DE19936911A1 (de) | 1999-08-05 | 2001-02-08 | Henkel Kgaa | Mittel zum Färben von keratinhaltigen Fasern |
| JP2003535813A (ja) * | 1999-08-20 | 2003-12-02 | ユニメッド・ファーマシューティカルズ・インコーポレーテッド | 半水性溶媒中にデルタ−９−テトラヒドロカンナビノールを含んでなる吸入のための組成物 |
| GB9927555D0 (en) * | 1999-11-23 | 2000-01-19 | Bede Scient Instr Ltd | X-ray fluorescence apparatus |
| ES2280343T3 (es) * | 2000-03-09 | 2007-09-16 | Gw Pharma Limited | Composiciones farmaceuticas que contienen cannabis. |
| CA2435409A1 (fr) * | 2001-01-26 | 2002-08-01 | University Of Connecticut | Nouveaux ligands cannabimimetiques |
| AU2002231970B2 (en) | 2001-02-14 | 2007-08-16 | CNX Therapeutics Limited | Mucoadhesive pharmaceutical formulations |
| EP1321159A1 (fr) * | 2001-12-21 | 2003-06-25 | CHIESI FARMACEUTICI S.p.A. | Dispositif d'actionnement pour inhalateur doseur pressurisé avec orifices percés par laser |
-
2003
- 2003-08-14 PT PT03787900T patent/PT1542657E/pt unknown
- 2003-08-14 EP EP03787900A patent/EP1542657B8/fr not_active Expired - Lifetime
- 2003-08-14 AT AT03787900T patent/ATE533472T1/de active
- 2003-08-14 ES ES03787900T patent/ES2377819T3/es not_active Expired - Lifetime
- 2003-08-14 PL PL375224A patent/PL215220B1/pl active Protection Beyond IP Right Term
- 2003-08-14 KR KR1020057002528A patent/KR101008609B1/ko not_active Expired - Lifetime
- 2003-08-14 SI SI200332107T patent/SI1542657T1/sl unknown
- 2003-08-14 WO PCT/GB2003/003574 patent/WO2004016246A1/fr not_active Ceased
- 2003-08-14 ES ES10180523.2T patent/ES2625605T3/es not_active Expired - Lifetime
- 2003-08-14 PT PT101805232T patent/PT2314284T/pt unknown
- 2003-08-14 EP EP10180523.2A patent/EP2314284B1/fr not_active Expired - Lifetime
- 2003-08-14 CA CA2454644A patent/CA2454644C/fr not_active Expired - Lifetime
- 2003-08-14 MX MXPA05001567A patent/MXPA05001567A/es active IP Right Grant
- 2003-08-14 DK DK03787900.4T patent/DK1542657T3/da active
- 2003-08-14 DK DK10180523.2T patent/DK2314284T3/en active
- 2003-08-14 AU AU2003253005A patent/AU2003253005B2/en active Active
- 2003-08-14 JP JP2004528678A patent/JP4515908B2/ja not_active Expired - Lifetime
-
2009
- 2009-06-18 AU AU2009202434A patent/AU2009202434B2/en active Active
-
2012
- 2012-02-15 CY CY20121100154T patent/CY1112523T1/el unknown
-
2013
- 2013-06-26 LU LU92233C patent/LU92233I2/fr unknown
-
2014
- 2014-03-21 FR FR14C0025C patent/FR14C0025I2/fr active Active
Also Published As
| Publication number | Publication date |
|---|---|
| PL215220B1 (pl) | 2013-11-29 |
| ES2377819T3 (es) | 2012-04-02 |
| CA2454644A1 (fr) | 2004-02-14 |
| KR20050042157A (ko) | 2005-05-04 |
| CA2454644C (fr) | 2014-09-16 |
| EP2314284B1 (fr) | 2017-02-15 |
| EP1542657A1 (fr) | 2005-06-22 |
| CY1112523T1 (el) | 2015-12-09 |
| EP2314284A2 (fr) | 2011-04-27 |
| EP1542657B8 (fr) | 2012-03-14 |
| FR14C0025I1 (fr) | 2014-08-08 |
| KR101008609B1 (ko) | 2011-01-17 |
| SI1542657T1 (sl) | 2012-04-30 |
| AU2003253005B2 (en) | 2009-03-19 |
| PT1542657E (pt) | 2012-02-29 |
| PT2314284T (pt) | 2017-05-25 |
| PL375224A1 (en) | 2005-11-28 |
| EP1542657B1 (fr) | 2011-11-16 |
| EP2314284A3 (fr) | 2012-05-09 |
| MXPA05001567A (es) | 2005-04-25 |
| AU2009202434B2 (en) | 2012-08-30 |
| ES2625605T3 (es) | 2017-07-20 |
| AU2003253005A1 (en) | 2004-03-03 |
| JP2006504671A (ja) | 2006-02-09 |
| FR14C0025I2 (fr) | 2014-11-14 |
| WO2004016246A1 (fr) | 2004-02-26 |
| AU2009202434A1 (en) | 2009-07-09 |
| JP4515908B2 (ja) | 2010-08-04 |
| DK1542657T3 (da) | 2012-03-05 |
| ATE533472T1 (de) | 2011-12-15 |
| DK2314284T3 (en) | 2017-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR14C0025I1 (fr) | ||
| MXPA03010991A (es) | Composicion permeable a la piel que comprende inhibidor de ciclooxigenasa-a selectivo y alcohol monohidrico. | |
| BR9810729B1 (pt) | composição farmacêutica para compostos lipofìlicos ácidos disposta como uma formulação auto-emulsificante. | |
| ES2079210T3 (es) | Formulacion farmaceutica de aerosol. | |
| AR035927A1 (es) | Compuesto de lactama (n)-((s)-2-hidroxi-3-metilbutiril)-1-(l-alaninil)-(s)-1-amino-3-metil-4,5,6,7-tetrahidro-2h-3-benzazepin-2-ona , composicion farmaceutica que lo comprende, procedimiento para la inhibicion de la liberacion de peptido b-amiloide y/o su sintesis que lo emplea y su uso para la fabr | |
| CA2423568A1 (fr) | Derives de glucopyranosiloxybenzylbenzene et compositions therapeutiques contenant ces composes | |
| KR950007841A (ko) | 트라마돌 염을 함유하는 서방성 약물 제제 | |
| US20190374508A1 (en) | Therapeutic topical compositions of apremilast | |
| DE122011100060I1 (de) | Cannabis enthaltende pharmazeutische zusammensetzungen. | |
| KR950703932A (ko) | 안정화된 의학용 에어로졸 용액 제제(Stabilized medicinal aerosol solution formulations) | |
| ES2178430T3 (es) | Utilizacion de composiciones farmaceuticas gelificables en parodontologia. | |
| AR033688A1 (es) | Composicion parenteral reconstituible | |
| ES2188092T3 (es) | Composicion de aerosol. | |
| AR032138A1 (es) | Derivados de 6-hidroxi-indazol, una composicion oftalmica, y el uso de dichos derivados para la manufactura de un medicamento para el tratamiento de glaucoma | |
| JP2009149692A (ja) | ゲル軟膏 | |
| CO5580741A2 (es) | Composicion farmaceutica que comprende un agonista de receptor de 5ht1 | |
| CL2004001325A1 (es) | Una composicion farmaceutica de aerosol que comprende cilesonida solubilizada en un propelente hidrofluorocarbono y un co-solvente, de preferencia etanol, util como antiinflamatorio de las vias aereas. | |
| KR970032872A (ko) | 아세틸살리실산을 함유하는 피부 손상 처치용 약물 | |
| BR0109747A (pt) | Uso de 5-(2-pirazinil)-4-metil-1-2-ditiol-3-tiona (oltipraz) como um medicamento, composição farmacêutica para a prevenção e tratamento da progressão da fibrose hepática, uso de 5-(2-pirazinil)-4-metil-1, 2-ditiol-3-tiona e método para a prevenção e tratamento da progressão da fibrose e da cirrose hepática | |
| NO950134L (no) | Formuleringer for oralt administrerte farmasöytiske midler | |
| KR970706802A (ko) | 저압-타정된 발포 제제(low-pressure tableted effervescent preparation) | |
| JP2006527764A (ja) | ジアゼパムを含有する経鼻マイクロエマルジョン | |
| EP1423126A2 (fr) | Traitement d'etats hyperproliferatifs des surfaces corporelles | |
| AU2002320964A1 (en) | Treatment of hyperproliferative conditions of body surfaces | |
| JP2007077143A (ja) | アシタザノラスト含有組成物 |